Atossa Therapeutics Inc.
ATOS | NASDAQ
$2.29
+$0.04 (+1.78%)
Sep 22, 2026, 2:15 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -2.19 | -4.72 | -3.67 | -2.52 | -8.89 | -0.48 |
PEG Ratio | -0.06 | 0.28 | -0.26 | -0.15 | 0.10 | 0.16 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 1.94 | 1.66 | 1.22 | 0.57 | 1.35 | 0.40 |
P/FCF Ratio | -2.56 | -5.64 | -5.29 | -3.23 | -11.35 | -0.93 |
P/OCF Ratio | -2.56 | -5.65 | -5.30 | -3.23 | -11.36 | -0.93 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | n/a | n/a | n/a | n/a | n/a | 0 |
Quick Ratio | 5.53 | 14.99 | 17.33 | 20.29 | 45.18 | 2.73 |
Current Ratio | 5.53 | 14.99 | 17.61 | 21.23 | 45.18 | 2.73 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -88.35% | -35.68% | -33.06% | -22.85% | -14.92% | -65.62% |
Return on Assets | -73.03% | -33.36% | -31.27% | -21.82% | -14.59% | -41.61% |
Return on Invested Capital | -94.38% | -38.64% | -34.47% | -23.47% | -14.86% | -53.69% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove ATOS